Phimedix PLC AIM Rule 15 Update (0924R)

TIDMPHM

RNS Number : 0924R

Phimedix PLC

03 March 2021

3 March 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Phimedix Plc

("Phimedix" or "the Company")

AIM Rule 15 Update

Further to its announcement on 18 January 2021, Phimedix (AIM: PHM), the AIM Rule 15 cash shell, announces that the proposed acquisition in the life sciences space will not now be proceeding.

As no reverse takeover will be completed by 14 March 2021, being the date six months following the suspension of trading in the Company's shares, the London Stock Exchange will cancel the admission of Phimedix's ordinary shares to trading on AIM ("Cancellation") with effect from 7.30 a.m. on Monday 15 March 2021.

After Cancellation, the Company will explore its available options, and keep shareholders informed as and when appropriate.

 
 Phimedix Plc 
  Nicholas Nelson, Director                        Please email any enquiries 
  Ajay Rajpal, Director                               to [e-mail] 
 
   SPARK Advisory Partners Limited (Nominated 
   Adviser) 
   Mark Brady or James Keeshan 
   www.sparkadvisorypartners.co m                               0203 368 3550 
 
   SI Capital Limited (Broker) 
   Nick Emerson 
   www.sicapital.co.uk                                           01483 413500 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FURJJMRTMTTMBFB

(END) Dow Jones Newswires

March 03, 2021 12:28 ET (17:28 GMT)